Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...

Denali Therapeutics (NASDAQ:DNLI) shares plunged 7% after its ALS treatment, DNL343, failed to meet its primary endpoint in a phase 2/3 study, according to topline results. The primary endpoint ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...